Navigation Links
Amgen's Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
Date:7/30/2013

ent and future products, sales growth of recently launched products, competition from other products (domestic or foreign), and difficulties or delays in manufacturing our products.  In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.  We or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions.  Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  Discovery or identification of new pr
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
2. Oncology remains most restrictive specialty for second year
3. China Biologic Products to Report Second Quarter 2013 Financial Results
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
5. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
6. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
7. VirtualScopics Schedules Second Quarter 2013 Earnings Announcement
8. Luminex Corporation Reports Second Quarter 2013 Results
9. Endo to Announce Second Quarter 2013 Financial Results on August 6, 2013
10. Simcere Pharmaceutical Group to Announce Second Quarter 2013 Financial Results on Tuesday, August 13, 2013
11. PDI, Inc. to Hold Second Quarter 2013 Financial Results Conference Call on Monday, August 5, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Rigrodsky & Long, P.A.: , Do ... LCI )? , Did you purchase your shares ... 16, 2014, inclusive? , Did you lose money in ... want to discuss your rights? Rigrodsky ... Timothy J. MacFall , announces that a complaint has been ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces that ... its catalogue: Germany Aesthetic Lasers and ... http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Germany Aesthetic ... Summary GlobalData,s new report, "Germany Aesthetic ... provides key market data on the Germany Aesthetic ...
(Date:8/28/2014)... Pharmatech initiated enrollment for its AccessPPM ... method for matching cancer patients to cancer clinical ... specific cancers, disease staging, and genetic mutations - ... in the first place. The challenge that the ... be well known to the patient or even ...
Breaking Medicine Technology:Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2
... time you consider popping a,pill when you have trouble ... senior psychiatrist at the Scripps Clinic Sleep Center in ... regularly can,increase the risk of skin cancer., Daniel ... studies,involving sleeping pills and cancer, has just been published ...
... Research Relationships and Proven, Track Record ... SANTA CLARA, Calif., Aug. 18 NewCardio, Inc.,(OTC ... company, today,announced that Vincent W. Renz has joined ... Company,s commercialization effort, to include,business development, client services, ...
Cached Medicine Technology:Prescription Sleeping Pill Use Tied to Cancer 2Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4
(Date:8/28/2014)... American adults who are beginning to ... will now have a simpler way to connect with ... this year, some of the best life insurance rates ... , The promoted plans that included price data revealed ... popular policies. The term, guaranteed and modified plans that ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 ... bellwether trial of a transvaginal mesh lawsuit ( ... Inc., Bernstein Liebhard LLP reports. Court documents pending ... West Virginia indicate that the case was filed ... undergo two revision surgeries, allegedly due to vaginal ...
(Date:8/28/2014)... Vernon, Ind. (PRWEB) August 28, 2014 ... of Valero Energy Corporation (NYSE: VLO), and the Ports ... state and local officials today at a Port Appreciation ... purchased Mount Vernon ethanol plant. , “The opening of ... Vernon is another economic development win for the ...
(Date:8/28/2014)... take wing? Did they fall from trees and learn to ... along the ground and pump their "arms" to get aloft? ... past, but a new University of California, Berkeley, study provides ... ability to maneuver in midair, a talent that could have ... a perch. , The study looked at how baby birds, ...
(Date:8/28/2014)... of Medicine published research results on Aug. 21 ... safely reduce the viral load and clinical illness of ... (RSV). , Le Bonheur Children,s Hospital and ... Disease Specialist John DeVincenzo, MD, is lead author of ... common cause of lower respiratory tract infections in young ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:DeVincenzo study breakthrough in RSV research 2
... will save lives this holiday season, NEW ... Friday" and the holiday season, New York Blood ... the children and,families whose lives are stricken by ... survival. Among these diseases are: Leukemia,and other forms ...
... efforts through second Innovation Event, INDIANAPOLIS, ... WLP ), the,nation,s largest health insurance company ... will begin accepting applications for its second ... innovation,partnership efforts by providing an accelerated process ...
... lead to vaccine that works , , THURSDAY, Nov. 13 (HealthDay ... has failed, but researchers report that they,ve still gained insight ... "It,s raised a whole new set of questions that are ... to a successful vaccine," said Dr. Susan P. Buchbinder, lead ...
... ... hospitals, ... announced HealthBIT, a healthcare business intelligence platform for,hospitals. HealthBIT(TM) provides ... and comparing their,data to provide actionable opportunities that result in ...
... shows economic,stress takes toll on the emotional and ... conducted by the American Psychological Association, shows,at least ... economy as their top,stressors. More than half, reported ... anger. Forty-six percent indicated they,were worried about providing ...
... options dwindle or are exhausted, terminally ill-patients often ... therapies. However, a team of researchers from Wake ... Medical Center and Unity Health System, report that ... governing end-of-life care may be leaving many medical ...
Cached Medicine News:Health News:A Thanksgiving Message From New York Blood Center 2Health News:A Thanksgiving Message From New York Blood Center 3Health News:WellPoint Announces Second Annual Innovation Event 2Health News:WellPoint Announces Second Annual Innovation Event 3Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform 2Health News:Economic Stress Takes Toll on Health 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 3
For the quantitative in vitro determination of CK-MB in serum and plasma...
The ALT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alanine aminotransferase activity in serum or plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... S-1™ Biodegradable Anteroir Cervical System, in conjunction ... with a collar), is intended for use ... fusion procedures as a means to maintain ... or autografts., This device is not intended ...
Medicine Products: